Basis of Presentation and Significant Accounting Policies (Details)		1 Months Ended							3 Months Ended		70 Months Ended
	Jan. 07, 2020 USD ($)	Oct. 31, 2021 ft²	Jun. 30, 2021 ft²	Dec. 31, 2019 USD ($)	Oct. 31, 2017 USD ($)	May 31, 2017 USD ($)	Jun. 30, 2016 USD ($)	May 31, 2016 USD ($)	Mar. 31, 2022 USD ($) segment	Mar. 31, 2021 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Oct. 31, 2018	Sep. 30, 2018
Basis of Presentation and Significant Accounting Policies
Accumulated deficit									$ 173,839,540		$ 173,839,540	$ 165,718,953
Net loss									8,189,798	$ 7,623,140
Cash, cash equivalents and short term investments									84,100,000		84,100,000
Derivative warrant liability									$ 3,241	42,481	3,241	11,020	$ 33,779
Number of operating segments | segment									1
Revenue Recognition
Revenue									$ 212,418	538,645
Allowable expenses incurred under NIH grant									0
Revenue recognized under NIH grant									0	$ 0
Other Assets.
Other assets									$ 16,995,227		$ 16,995,227	$ 12,193,540
Morrisville, NC
Other Assets.
Area of facility to be leased | ft²			15,996
San Antonio, TX
Other Assets.
Area of facility to be leased | ft²		20,144
Shattuck Labs Inc. License Agreement [Member] | Shattuck
Deferred Revenue
Initial license fees							$ 50,000
Pelican Therapeutics, Inc.
Basis of Presentation and Significant Accounting Policies
Ownership interest in subsidiary									85.00%		85.00%	85.00%		85.00%	80.00%
Pelican Therapeutics, Inc.
Revenue Recognition
Amount awarded from CPRIT grant								$ 15,200,000
Grant revenue | Maximum
Revenue Recognition
Amount awarded from NIH grant	$ 224,713
Grant revenue | Pelican Therapeutics, Inc.
Revenue Recognition
Revenue											$ 15,200,000
Remaining grant amount receivable									$ 1,500,000		$ 1,500,000
Grant revenue | Pelican Therapeutics, Inc. | Maximum
Revenue Recognition
Amount awarded from CPRIT grant							$ 15,200,000
Grant revenue | Tranche 1 | Pelican Therapeutics, Inc.
Revenue Recognition
Revenue						$ 1,800,000
Grant revenue | Tranche 2 | Pelican Therapeutics, Inc.
Revenue Recognition
Revenue					$ 6,500,000
Grant revenue | Tranche 3 | Pelican Therapeutics, Inc.
Revenue Recognition
Revenue				$ 5,400,000